CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011		Jun. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 326,802		$ 192,730
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income tax expense (benefit)	52,156		(18,059)
Shortfall tax benefits from stock-based compensation	(331)		(559)
Depreciation and amortization	93,389		106,724
Stock-based compensation expense	16,950		21,630
Amortization of debt discount and debt issuance costs	32,776		35,692
Changes in fair value of investments	(264,208)
Loss (gain) on foreign exchange contracts	(5,089)		9,499
Impairment and (gain) loss on sale of assets	54,056
Other	23,090		3,752
Changes in operating assets and liabilities, net of acquisitions:
Receivables	(37,532)		(25,581)
Inventory	5,646		18,985
Other assets	1,207		9,474
Accounts payable and accrued expenses	(11,445)		23,955
Other liabilities	(65,462)		(189)
Net cash provided by operating activities	222,005		378,053
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(28,049)		(22,997)
Proceeds from sale of property and equipment	818
Cash balance from consolidation of variable interest entity	15,513
Acquisition of Mepha GmbH, net of cash acquired			(549,463)
Acquisition of GeminX Pharmaceuticals, Inc., net of cash acquired	(184,198)
Acquisition of ChemGenex Ltd., net of cash acquired	(179,931)
Purchases of investments	(135,453)		(60)
(Cash settlements of) proceeds from foreign exchange contracts	7,111		(9,499)
Net cash used for investing activities	(504,189)		(582,019)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under the employee stock purchase plan	349
Proceeds from exercises of common stock options	133,703		14,370
Windfall tax benefits from stock-based compensation	12,060
Acquisition of treasury stock			(33)
Payments on and retirements of long-term debt	(35,763)		(221,478)
Acquisition of Ception Therapeutics, Inc. noncontrolling interest			(299,289)
Acquisition of ChemGenex Ltd. noncontrolling interest	(6,602)
Net cash provided by (used for) financing activities	103,747		(506,430)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	15,674		(9,793)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(162,763)		(720,189)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,160,239		1,647,635
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 997,476	[1]	$ 927,446

[1] Amounts include assets and liabilities of our variable interest entities (VIEs). Our interests and obligations with respect to VIEs' assets and liabilities are limited to those accorded to us in our agreements with our VIEs. See Note 2 to these consolidated financial statements for amounts.